Leucine-Rich Repeat Serine-Threonine Protein Kinase-2
"Leucine-Rich Repeat Serine-Threonine Protein Kinase-2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A serine/threonine protein kinase with GTPase activity that contains 12 LEUCINE-rich repeats in its central region and 7 WD repeats C-terminal to its kinase and GTPase domains. It localizes to TRANSPORT VESICLES; the OUTER MITOCHONDRIAL MEMBRANE; and the GOLGI APPARATUS. It functions in PROTEIN TRANSPORT; regulates neuron morphology in the central nervous system, and also functions in the trafficking of SYNAPTIC VESICLES. Mutations in the LRRK2 gene have been identified in autosomal dominant cases of PARKINSON DISEASE (PARK8).
Below are MeSH descriptors whose meaning is more general than "Leucine-Rich Repeat Serine-Threonine Protein Kinase-2".
Below are MeSH descriptors whose meaning is more specific than "Leucine-Rich Repeat Serine-Threonine Protein Kinase-2".
This graph shows the total number of publications written about "Leucine-Rich Repeat Serine-Threonine Protein Kinase-2" by people in this website by year, and whether "Leucine-Rich Repeat Serine-Threonine Protein Kinase-2" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "Leucine-Rich Repeat Serine-Threonine Protein Kinase-2" by people in Profiles.
The E3 ligase TRIM1 ubiquitinates LRRK2 and controls its localization, degradation, and toxicity. J Cell Biol. 2022 04 04; 221(4).
Evaluation of the interaction between LRRK2 and PARK16 loci in determining risk of Parkinson's disease: analysis of a large multicenter study. Neurobiol Aging. 2017 01; 49:217.e1-217.e4.
Selective expression of Parkinson's disease-related Leucine-rich repeat kinase 2 G2019S missense mutation in midbrain dopaminergic neurons impairs dopamine release and dopaminergic gene expression. Hum Mol Genet. 2015 Sep 15; 24(18):5299-312.
LRRK2 regulates synaptogenesis and dopamine receptor activation through modulation of PKA activity. Nat Neurosci. 2014 Mar; 17(3):367-76.
Protective effect of LRRK2 p.R1398H on risk of Parkinson's disease is independent of MAPT and SNCA variants. Neurobiol Aging. 2014 Jan; 35(1):266.e5-14.
Population-specific frequencies for LRRK2 susceptibility variants in the Genetic Epidemiology of Parkinson's Disease (GEO-PD) Consortium. Mov Disord. 2013 Oct; 28(12):1740-4.
Genetic susceptibility loci, environmental exposures, and Parkinson's disease: a case-control study of gene-environment interactions. Parkinsonism Relat Disord. 2013 Jun; 19(6):595-9.
Don't move: LRRK2 arrests NFAT in the cytoplasm. Nat Immunol. 2011 Oct 19; 12(11):1029-30.
Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study. Lancet Neurol. 2011 Oct; 10(10):898-908.
Do interactions between SNCA, MAPT, and LRRK2 genes contribute to Parkinson's disease susceptibility? Parkinsonism Relat Disord. 2011 Dec; 17(10):730-6.